Lv7
4850 积分 2023-02-12 加入
First-line therapy of osimertinib with chemotherapy in Chinese patients with EGFR mutation–positive non–small cell lung cancer: protocol for a multicenter, prospective, observational study
9个月前
已完结
Neoadjuvant vs Adjuvant Chemoimmunotherapy for Stage II-IIIB Non-Small Cell Lung Cancer
11个月前
已完结
Immunotherapy With or Without Chemotherapy in Advanced NSCLC—A Delicate Balance of Harm and Benefit
11个月前
已完结
Letter to the Editor: 'CNS Outcomes of Osimertinib Plus Chemotherapy in Patients with EGFR Mutation-Positive Lung Cancer Beyond Osimertinib Progression'
11个月前
已关闭
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)
11个月前
已完结
Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study
11个月前
已完结
Management of EGFR-Variant and ALK-Positive Non–Small Cell Lung Cancer Brain Metastasis
11个月前
已完结
The role of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer at different risks of brain metastasis: A multicenter retrospective study
11个月前
已完结
Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib
11个月前
已完结
皖公网安备34019202002308
